Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Depression present in late life and midlife significantly increased the risk for all-cause dementia based on pooled hazard ratios (hazard ratios, 1.95 and 1.56, respectively). HealthDay News — ...

There was no significant sex differences in toddlers with autism spectrum disorder across 17 of 18 measures, including symptom severity, receptive and expressive language, and social attention.

A quality improvement strategy can improve electronic health record-based screening for depression and anxiety in people with epilepsy.

The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

Spinal cord stimulation can reduce pain and restore nerve function among patients with diabetic peripheral neuropathy.

The FDA has approved Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.

Central hypersomnolence disorders, such as narcolepsy type 2 and idiopathic hypersomnia, are associated with reduced health-related quality of life.

For US adult cancer survivors with a new alcohol use disorder diagnosis, the 1-year cumulative incidence of treatment initiation was 14.3%.

Patients with Alzheimer disease and cognitive impairment with delayed REM sleep patterns have increased levels of brain amyloid and tau.

Shifting patterns in ischemic stroke mortality and death locations across US populations highlight disparities and end-of-life care needs.

For adult patients with transient ischemic attack/mild stroke, disturbed sleep is associated with greater cerebral small vessel disease burden and worse cognitive outcomes.